§ 1396u–7.
(b)
Benchmark benefit packages
(1)
In general
For purposes of subsection (a)(1), subject to paragraphs (5) and (6), each of the following coverages shall be considered to be benchmark coverage:
(A)
FEHBP-equivalent health insurance coverage
(B)
State employee coverage
(C)
Coverage offered through HMO
The health insurance coverage plan that—
(ii)
has the largest insured commercial, non-medicaid enrollment of covered lives of such coverage plans offered by such a health maintenance organization in the State involved.
(D)
Secretary-approved coverage
(2)
Benchmark-equivalent coverage
For purposes of subsection (a)(1), subject to paragraphs (5) and (6)
1
So in original. Probably should be followed by a comma.
coverage that meets the following requirement shall be considered to be benchmark-equivalent coverage:
(A)
Inclusion of basic services
The coverage includes benefits for items and services within each of the following categories of basic services:
(i)
Inpatient and outpatient hospital services.
(ii)
Physicians’ surgical and medical services.
(iii)
Laboratory and x-ray services.
(iv)
Coverage of prescription drugs.
(v)
Mental health services.
(vi)
Well-baby and well-child care, including age-appropriate immunizations.
(vii)
Other appropriate preventive services, as designated by the Secretary.
(B)
Aggregate actuarial value equivalent to benchmark package
(C)
Substantial actuarial value for additional services included in benchmark package
With respect to each of the following categories of additional services for which coverage is provided under the benchmark benefit package used under subparagraph (B), the coverage has an actuarial value that is equal to at least 75 percent of the actuarial value of the coverage of that category of services in such package:
(3)
Determination of actuarial value
The actuarial value of coverage of benchmark benefit packages shall be set forth in an actuarial opinion in an actuarial report that has been prepared—
(A)
by an individual who is a member of the American Academy of Actuaries;
(B)
using generally accepted actuarial principles and methodologies;
(C)
using a standardized set of utilization and price factors;
(D)
using a standardized population that is representative of the population involved;
(E)
applying the same principles and factors in comparing the value of different coverage (or categories of services);
(F)
without taking into account any differences in coverage based on the method of delivery or means of cost control or utilization used; and
(G)
taking into account the ability of a State to reduce benefits by taking into account the increase in actuarial value of benefits coverage offered under this subchapter that results from the limitations on cost sharing under such coverage.
The actuary preparing the opinion shall select and specify in the memorandum the standardized set and population to be used under subparagraphs (C) and (D).
(4)
Coverage of rural health clinic and FQHC services
Notwithstanding the previous provisions of this section, a State may not provide for medical assistance through enrollment of an individual with benchmark coverage or benchmark equivalent coverage under this section unless—
(6)
Mental health services parity
(7)
Coverage of family planning services and supplies
(8)
COVID–19 vaccines, testing, and treatment
Notwithstanding the previous provisions of this section, a State may not provide for medical assistance through enrollment of an individual with benchmark coverage or benchmark-equivalent coverage under this section unless, during the period beginning on
March 11, 2021, and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in
section 1320b–5(g)(1)(B) of this title, such coverage includes (and does not impose any deduction, cost sharing, or similar charge for)—
(A)
COVID–19 vaccines and administration of the vaccines; and
(B)
testing and treatments for COVID–19, including specialized equipment and therapies (including preventive therapies), and, in the case of such an individual who is diagnosed with or presumed to have COVID–19, during the period such individual has (or is presumed to have) COVID–19, the treatment of a condition that may seriously complicate the treatment of COVID–19, if otherwise covered under the State plan (or waiver of such plan).
([Aug. 14, 1935, ch. 531], title XIX, § 1937, as added [Pub. L. 109–171, title VI, § 6044(a)], Feb. 8, 2006, [120 Stat. 88]; amended [Pub. L. 111–3, title VI, § 611(a)]–(c), Feb. 4, 2009, [123 Stat. 100], 101; [Pub. L. 111–148, title II], §§ 2001(a)(5)(E), (c), 2004(c)(2), 2303(c), Mar. 23, 2010, [124 Stat. 275], 276, 283, 296; [Pub. L. 116–260, div. BB, title II, § 203(a)(4)(B)], div. CC, title II, §§ 209(a)(2), 210(c), Dec. 27, 2020, [134 Stat. 2917], 2986, 2991; [Pub. L. 117–2, title IX, § 9811(a)(5)], Mar. 11, 2021, [135 Stat. 211].)